Becton, Dickinson and Company BDX, popularly known as BD, recently completed enrollment for its PREVENT clinical trial evaluating Phasix Mesh for preventing incisional hernias in high-risk patients undergoing elective open midline abdominal surgery.
For investors, the milestone reinforces BD's strategy of expanding its advanced tissue regeneration franchise through clinically backed innovation rather than relying solely on new product launches. Management has identified advanced tissue regeneration as one of its fastest-growing platforms, with double-digit growth and multiple clinical trials underway to broaden Phasix Mesh into new indications, making successful PREVENT data and a planned FDA submission a potential long-term growth catalyst.
Likely Trend of BDX Stock Following the News
Following the announcement of the news, BDX shares have traded flat. In the year-to-date period, shares of the company have lost 2.6% against the industry’s 5.1% increase. However, the S&P 500 has risen 12.2% in the same timeframe.
The PREVENT enrollment milestone strengthens BD's long-term growth outlook by expanding Phasix Mesh beyond hernia repair into the largely untapped incisional hernia prevention market, where no products are currently approved in the United States. Successful 24-month data could support an FDA submission, open a new commercial opportunity while reinforcing the company's evidence-driven innovation strategy. The development also aligns with management's broader focus on advanced tissue regeneration, which has been delivering double-digit growth and remains a key long-term growth platform supported by multiple clinical expansion programs.
BDX currently has a market capitalization of $51.69 billion.
Image Source: Zacks Investment Research
More on the News
The PREVENT trial represents a key milestone in BD's effort to expand the use of its Phasix Mesh beyond traditional hernia repair into incisional hernia prevention, an area with a significant unmet medical need following abdominal surgery. The study enrolled 477 patients across 32 clinical sites in the United States and Europe, making it the first large-scale randomized trial to evaluate prophylactic reinforcement with a resorbable mesh for this indication, where no products currently have regulatory approval.
According to Rian Seger, worldwide president of Surgery at BD, the trial builds on the company's long-standing expertise in abdominal wall surgery while generating clinical evidence that could broaden the use of regenerative technologies for patients at risk of post-surgical complications.
The trial is designed to evaluate Phasix Mesh in high-risk patients undergoing elective open midline abdominal surgery, with the goal of establishing robust clinical evidence for preventing incisional hernias. Patients will be followed through the study's primary endpoint at 24 months, while longer-term follow-up extending to five years will further assess safety and clinical outcomes.
Upon completion of the primary endpoint assessments, BD expects the findings to support a planned submission to the FDA, potentially paving the way for a label expansion into a new preventive surgical indication. The milestone also aligns with management's broader strategy, outlined during its fiscal third-quarter earnings call, of using multiple clinical programs to expand the advanced tissue regeneration platform into new indications as a long-term growth driver.
Advanced Tissue Regeneration Pipeline Extends Beyond PREVENT
Beyond the PREVENT study, BD is advancing multiple clinical trials aimed at expanding its advanced tissue regeneration portfolio into new applications. Management said that the Phasix biomaterial platform remains one of the company's key long-term growth drivers, with several ongoing studies evaluating its use across additional indications beyond abdominal wall surgery. The company expects these evidence-generation efforts, alongside continued double-digit growth in the business, to strengthen its presence in regenerative surgery and support future commercial expansion.
Other News
Recently, BD exited the third quarter of fiscal 2026 with better-than-expected results and solid top- and bottom-line results. Robust performances by all segments and both geographic regions were encouraging.
Apart from these, there were a few other developments during the recent period. BDX was awarded a Vizient Innovative Technology contract for the BD CentroVena One Insertion System.
The company launched the Elyra Thulium Fiber Laser System, thus expanding its kidney stone care portfolio. BD also announced a collaboration with Brazil-based pharmaceutical company EMS to expand access to GLP-1 therapies through a semaglutide launch utilizing BD's Vystra Injection Pen platform to support consistent, reliable self-injection for patients with obesity and type 2 diabetes.
BDX’s Zacks Rank & Key Picks
Currently, BDX carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical GMEDÂ West Pharmaceutical WST and The Cooper Companies COO.
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.
COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.Â
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Â
Â
Â
Â
(0) comments
Welcome to the discussion.
Log In
Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.